NCT04923620

Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

Efficacy and Safety of Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy for RAS Wild-type Locally Advanced Rectal Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 51 (estimated)
• Sponsor: Shanghai Minimally Invasive Surgery Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer

Conditions

• Neoadjuvant Treatment
• Rectal Cancer
• Cetuximab
• Radiotherapy

Interventions

Type	Name	Description
DRUG	cetuximab+mFOLFOX6	cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
RADIATION	short-course radiotherapy	25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6

Timeline

• Start date: 2021-10-20
• Primary completion: 2024-08-31
• Completion: 2025-06-01
• First posted: 2021-06-11
• Last updated: 2024-02-26

Locations

1 site across 1 country: China